SCHEMBL23836665

SCHEMBL23836665

CCCCC(C)(CC)C[C@H](N)C(=O)NCC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.39
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
PTGS2 P35354 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
RRM1 P23921 1/20 0.36
S1PR1 P21453 6/20 0.36
S1PR3 Q99500 6/20 0.36
S1PR2 O95136 5/20 0.36
S1PR5 Q9H228 4/20 0.36
PLA2G2A P14555 1/20 0.36
MME P08473 1/20 0.36
ACE P12821 1/20 0.36
CPA1 P15085 1/20 0.36
ACE2 Q9BYF1 1/20 0.36
FAAH O00519 1/20 0.35
GNAI3 P08754 1/20 0.35
GNAO1 P09471 1/20 0.35
GNAI1 P63096 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18712169 0.80 DPP7 (0.45) DPP7TDP1RRM1S1PR1S1PR3
SCHEMBL13968330 0.80 SLC1A2 (0.47) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL18712170 0.76 ALDH1A1 (0.47) DPP7ALDH1A1LMNAMAPTPTGS2
SCHEMBL23836662 0.76 ALDH1A1 (0.47) DPP7ALDH1A1LMNAMAPTPTGS2
SCHEMBL27637992 0.75 DPP7 (0.66) DPP7ALDH1A1LMNAMAPTPTGS2
SCHEMBL29472047 0.75 DPP7 (0.66) DPP7ALDH1A1LMNAMAPTPTGS2
SCHEMBL23974045 0.74 GRIK1 (0.50) MAPTSLC1A2SLC1A1SLC1A3GRIK1
SCHEMBL25006937 0.73 SLC1A2 (0.50) SLC1A2SLC1A1SLC1A3GRIK1GRIK2
SCHEMBL17941558 0.71 DPP7 (0.50) DPP7ALDH1A1LMNAMAPTPTGS2
SCHEMBL17941556 0.71 DPP7 (0.50) DPP7ALDH1A1LMNAMAPTPTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11124525-B2 Heteroaryl compounds useful as MK2 inhibitors CELGENE CAR LLC (BM) 2021-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11124525-B2 Heteroaryl compounds useful as MK2 inhibitors MKNK2, MKRN3, MKNK1 DPP7 1580/4885ALDH1A1 4142/4885LMNA 4553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.